预约演示

AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy

2024-04-25

交易

并购疫苗临床3期免疫疗法

AstraZeneca delivered a strong start to 2024 as both oncology and biopharmaceutical divisions surpassed $5 billion quarterly sales for the first time.

AstraZenecaZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin.

To heaAstraZenecal Soriot explain it, the deals were made to build the company’s future.

“This portfolio actually gives us the opportunity to combine,” Soriot said on the company’s first-quarter earnings call.

In oncology, AZ last month unveiled a $2 billion deal to acquire targeted radiotherapy specialist Fusion Pharmaceuticals. It followed a $1 billion buyout unveiled in December for the cell therapy biotech Gracell Biotechnologies. These add to AZ’s existing checkpoint inhibitor offerings and antibody-drug conjugate capabilities as well as an emerging portfolio of bispecific antibodies.

In the cardiovascular and metabolic disease field, AZ in November said it would pay $185 million uFusion Pharmaceuticalsn oral GLP-1 agonist from Eccogene. AZ has said the drug may hold potential for combGracell Biotechnologies its SGLT2 agent Farxiga.

As for vaccines, AZ in Decmetabolic diseaseo an agreement to acquire Icosavax, which has a protein virus-like particle platformGLP-1a phase 3-readEccogeneccine candidate.Farxiga

“I think there’s sometimes a misperception of what we’re trying to doIcosavaxl said. “We’re not trying to build a vaccine business like vaccine companies have. We are actually targeting vaccines that will be […] synergistic to oncology or respiratory disease products.”

With that synergy strategy, Soriot argued that the company is not stretching too thin.oncology respiratory disease

“The challenge and the opportunity in our industry is always to be able to think about today, but also the long term,” the chief executive said.

But M&A activities—at least in terms of technology platform deals—will slow down at AZ, Soriot added.

“I think we have acquired and built most of what we need for now and we need to execute on what we’ve got,” Soriot said. “But it doesn’t mean of course BD will come down to zero.”

Soriot’s comment comes as AstraZeneca delivered a strong start to 2024 as both oncology and biopharmaceutical divisions surpassed $5 billion quarterly sales for the first time and rare disease crossed the $2 billion mark. In a Thursday note to clients, ODDO BHF analysts called the results “much stronger than expected.”

AZ’s total revenue, which AstraZenecath product sales and alliance revenue, beat analysts’ estimates by 7%, reaching $12.7 billion in the first quarter.

The stellar performance was surprisingly driven in a large part by the 10-year-old Farxiga. As it nears a mandated price cut under the Inflation Reduction Act, the SGLT2 inhibitor brought in $1.89 billion sales. The number marked a 45% growth year over year and handily beat Wall Street’s consensus projection by 19%, according to ODDO BHF.

The launch of an authorized generic in the U.S. helped fuel Farxiga’s jump because Farxigars a low-cost option for patients, the company’s biopharmaceuticals chief SGLT2Dobber told investors during a call Thursday. Dobber declined to offer a sales breakdown between the two versions of Farxiga.

While Farxiga saw “solid growth” in emerging markets despite generic competition in some countries, Dobber warned that the drug is expected to be included in China’s volume-based procurement program later this year. The Chinese initiative, which targets off-patent drugs, will mean pricFarxigand likely market share loss.

Still, investors have most of their attention on some newer drugs, including in the oncology department.

HER2-targeted Enhertu generated $879 million sales in the first quarter between AZ and its partner Daiichi Sankyo. The antibody-drug conjugate enjoyed “sequential market share growth” in HER2-positive metastatic breast cancer and “continued adoption” in HER2-low disease, AZ’s oncology business head Dave Fredrickson said on the call.

AZ and DaiichiEnhertu to report data from the DESTINY-Breast06 trial by June, which could move EnheDaiichi Sankyoarlier into second-line HER2-low breast cancer and potentially in patientsHER2-positive metastatic breast canceran the current HER2-low definHER2-low disease HER2-lowhe trial has already reached primary completion about a month ago, which means the data necessary for the primary endpoint analysis were all in.

In oncoDaiichiagrisso remained the biggest drug with nearly $1.6 billion in sales in the first Enhertu, good for 15% growth year over yeaHER2-low breast cancer HER2-lowhanged exchange rates. The EGFR inhibitor looks on track to reach patientHER2th unresectable stHER2-lowGFR-mutant non-small cell lung cancer after a recent phase 3 trial win.